Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn Sells 2,845 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,845 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $140,400.75. Following the sale, the chief operating officer now directly owns 269,199 shares in the company, valued at approximately $13,284,970.65. This represents a 1.05 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Thursday, January 23rd, Patrick John Finn sold 2,422 shares of Twist Bioscience stock. The stock was sold at an average price of $50.17, for a total transaction of $121,511.74.
• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00.

Twist Bioscience Stock Up 3.2 %

Shares of TWST opened at $53.66 on Thursday. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The company has a 50 day moving average of $48.74 and a 200-day moving average of $46.27.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The business had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same period last year, the business earned ($0.75) earnings per share. The firm’s revenue was up 24.1% on a year-over-year basis. On average, sell-side analysts predict that Twist Bioscience Co. will post -2.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. US Bancorp DE lifted its holdings in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in Twist Bioscience during the 4th quarter valued at $1,427,000. ARK Investment Management LLC lifted its holdings in Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after purchasing an additional 237,772 shares during the last quarter. Handelsbanken Fonder AB acquired a new stake in Twist Bioscience during the 4th quarter valued at $855,000. Finally, Ieq Capital LLC lifted its holdings in Twist Bioscience by 21.1% during the 4th quarter. Ieq Capital LLC now owns 62,034 shares of the company’s stock valued at $2,883,000 after purchasing an additional 10,800 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Leerink Partners upped their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. TD Cowen reiterated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research began coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Robert W. Baird increased their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.